Yesterday Replidyne (NASDAQ: RDYN) held their annual shareholder meeting and 1Q08 conference call. With an anticipated burn rate of approximately $10M per quarter Replidyne’s current cash position just north of $78M positions operations to continue well into 2009. Considering the new strategic initiatives including restructuring, cash conservation and the difficult decision to terminate enrollment of the Phase III faropenem study management laid out the company plans to move forward with the C. difficile program with the goal of initiating a Phase I trial with REP 3123 as well as identifying an IND candidate from the DNA replication inhibition program. A spectrum of business development activity appears to be transpiring, though no details have been made public, some of which include: i) partnering talks are ongoing ii) looking at M&A opportunities, whereby the large cash position may make Replidyne more attractive to enable opportunistic actions and iii) a large international investment bank has been appointed to bring forth potential US and ROW opportunities, after all...the current market is frothy with deals. Needless to say with Replidyne’s seasoned and sophisticated management team it will not be surprising to see the share price and faropenem development pulled sharply out of their nose dives.
*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).